# Ukko

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ukko

- Industry: Pharmaceuticals
- Headquarters: Rehovot, Israel
- Website: www.ukko.us
- Total disclosed funding: $85M
- Latest round: Series C (Jan 8, 2026)
- Investors on record: 9

## About

Based in Tel Aviv, Israel, and founded in 2016, Ukko Inc. offers drugs intended to boost the immunity of an individual with food allergies and gluten-related disorders. In January 2026, Ukko Inc. raised USD 45 million in series C funding led by new investor Israel Biotech Fund, with participation from another new investor Sanara Capital. Returning investors Khosla Ventures, Leaps by Bayer, Fall Line Capital, and other unspecified investors also participated in the round.

The company operates as an artificial intelligence platform intended to uses patient samples, computational biology, immunology, and protein engineering to make proteins that do not trigger the immune system enabling proteins to be applied to the food and therapeutics markets.

Ukko Inc. intendes to use the funds to enter clinical trials with its investigational therapeutic for peanut strategy. accelerate the development of its gluten that is designed for people with celiac and other gluten sentivities.

The company plans to use the January 2026 funding to support its operations through 2027, including advancing the planned Phase 1/2a trial of its lead candidate UKK-0018.

## Funding rounds

- Series C, Jan 8, 2026, $45M — Khosla Ventures, Fall Line Capital, Israel Biotech Fund, Leaps by Bayer, Sanara Capital
- Series B, Jan 27, 2021, $40M — Khosla Ventures, Innovation Endeavors, Fall Line Capital, PeakBridge, Leaps by Bayer, Conti Ventures, Skyviews Life Science

## Investors

- Khosla Ventures (https://capitalatlas.ai/funds/khosla-ventures) — Series B, Series C
- Innovation Endeavors (https://capitalatlas.ai/funds/innovation-endeavors) — Series B
- Fall Line Capital (https://capitalatlas.ai/funds/fall-line-capital) — Series B, Series C
- PeakBridge (https://capitalatlas.ai/funds/peakbridge) — Series B
- Leaps by Bayer (https://capitalatlas.ai/funds/leaps-by-bayer) — Series B, Series C
- Conti Ventures — Series B
- Skyviews Life Science (https://capitalatlas.ai/funds/skyviews-life-science) — Series B
- Israel Biotech Fund (https://capitalatlas.ai/funds/israel-biotech-fund) — Series C
- Sanara Capital (https://capitalatlas.ai/funds/sanara-capital) — Series C